Aura Biosciences, Inc.
AURAHealthcare|Biotechnology|US
$6.56
+0.22 (+3.47%)
DCF Value
$0.67
Tangible Book / Share
$3.32
Cash / Share
$3.41
Financials
Financial Snapshot
Market Cap
$680.3M
Enterprise Value
$629.1M
Revenue (TTM)
$0.00
Net Income (TTM)
-$131.0M
Cash & Investments
$323.8M
Net Cash
$307.2M
Free Cash Flow (TTM)
-$102.7M
Operating CF (TTM)
-$102.3M
Debt/Equity
0.05
Cash Runway & Burn Rate
Cash on Hand
$323.8M
Quarterly Burn
$25.6M
Monthly Burn
$8.5M
Est. Runway
~12.7 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $32.5M | $17.4M | $149.1M | $188.8M | $226.2M | $151.1M | $144.2M | $323.8M | |
| Operating Cash Flow | -$20.7M | -$24.3M | -$32.4M | -$54.6M | -$63.8M | -$79.8M | -$84.7M | -$102.3M | |
| Free Cash Flow | -$22.9M | -$25.1M | -$34.5M | -$55.7M | -$64.6M | -$81.1M | -$85.2M | -$102.7M | |
| Capital Expenditure | -$2.2M | -$771.0K | -$2.1M | -$1.1M | -$709.0K | -$1.3M | -$447.0K | -$344.0K | |
| Financing Cash Flow | $39.7M | $10.0M | $166.3M | $95.6M | $97.3M | $1.6M | $77.2M | $469.2M |
R&D Spending
R&D (TTM)
$102.8M
R&D Intensity
—
R&D Growth vs Prior
+13.8%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $19.1M | $18.0M | $25.2M | $42.2M | $63.9M | $73.3M | $90.3M | $102.8M | |
| SG&A | $4.5M | $4.2M | $10.1M | $18.1M | $19.8M | $22.8M | $22.5M | $35.3M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $509.0K | $0.00 | $0.00 | $0.00 | $1.3M | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$509.0K | $0.00 | $0.00 | $0.00 | -$1.3M | $0.00 | $0.00 | $0.00 | |
| R&D | $19.1M | $18.0M | $25.2M | $42.2M | $63.9M | $73.3M | $90.3M | $102.8M | |
| SG&A | $4.5M | $4.2M | $10.1M | $18.1M | $19.8M | $22.8M | $22.5M | $35.3M | |
| Operating Income | -$24.1M | -$22.2M | -$35.3M | -$60.3M | -$85.0M | -$96.1M | -$112.8M | -$138.1M | |
| Interest Expense | $5.0K | $3.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$24.2M | -$22.2M | -$35.3M | -$58.8M | -$76.3M | -$86.8M | -$106.1M | -$130.9M | |
| Net Income | -$24.2M | -$22.2M | -$35.3M | -$58.8M | -$76.4M | -$86.9M | -$106.2M | -$131.0M | |
| EPS (Diluted) | -0.01 | -1.03 | -1.58 | -1.96 | -1.93 | -1.75 | -1.76 | -1.78 | |
| EBITDA | -$23.7M | -$21.4M | -$34.4M | -$57.6M | -$75.0M | -$85.6M | -$105.0M | -$132.3M | |
| Shares Out. (M) | 2921.96 | 29.22 | 29.21 | 29.94 | 39.62 | 49.65 | 60.34 | 94.86 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.5M | $17.4M | $149.1M | $121.6M | $41.1M | $31.7M | $59.5M | $67.8M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $67.2M | $185.1M | $119.4M | $84.7M | $256.0M | |
| Total Current Assets | $33.3M | $18.5M | $153.7M | $196.7M | $231.8M | $160.6M | $149.7M | $329.0M | |
| Total Assets | $37.1M | $22.1M | $160.0M | $223.9M | $255.1M | $182.5M | $169.4M | $348.1M | |
| Total Current Liabilities | $6.1M | $2.7M | $7.4M | $10.5M | $12.4M | $14.9M | $18.4M | $19.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $14.1M | $0.00 | |
| Total Liabilities | $6.3M | $2.7M | $7.7M | $28.4M | $29.2M | $30.5M | $32.5M | $32.9M | |
| Stockholders' Equity | $30.8M | $19.4M | $152.3M | $195.6M | $225.8M | $152.0M | $136.9M | $315.3M | |
| Retained Earnings | -$94.7M | -$116.9M | -$152.1M | -$210.9M | -$287.3M | -$374.2M | -$480.4M | -$559.7M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.7M | -$24.3M | -$32.4M | -$54.6M | -$63.8M | -$79.8M | -$84.7M | -$102.3M | |
| Capital Expenditure | -$2.2M | -$771.0K | -$2.1M | -$1.1M | -$709.0K | -$1.3M | -$447.0K | -$344.0K | |
| Free Cash Flow | -$22.9M | -$25.1M | -$34.5M | -$55.7M | -$64.6M | -$81.1M | -$85.2M | -$102.7M | |
| Investing Cash Flow | -$2.2M | -$771.0K | -$2.1M | -$67.9M | -$114.0M | $68.8M | $35.6M | -$185.3M | |
| Financing Cash Flow | $39.7M | $10.0M | $166.3M | $95.6M | $97.3M | $1.6M | $77.2M | $469.2M | |
| Issuance of Stock | $0.00 | $0.00 | $78.7M | $8.5M | $3.2M | $1.6M | $77.2M | $265.4M | |
| Repurchase of Stock | -$13.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$39.1M | |
| Net Debt Issuance | -$37.0K | -$34.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $507.0K | $736.0K | $2.3M | $6.4M | $8.8M | $11.7M | $14.3M | $23.2M | |
| Net Change in Cash | $16.8M | -$15.1M | $131.7M | -$26.8M | -$80.5M | -$9.4M | $27.8M | $181.2M |
Dilution Tracker
Shares outstanding grew 106.5% over 5 years — significant dilution
Shares Outstanding
104M
5-Year Share Growth
+106.5%
Stock Issuance (TTM)
$265.4M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2921.96 | 29.22 | 29.21 | 29.94 | 39.62 | 49.65 | 60.34 | 94.86 | |
| Change vs Prior % | — | -99.0% | -0.0% | 2.5% | 32.3% | 25.3% | 21.5% | 57.2% | |
| Stock Issuance | $0.00 | $0.00 | $78.7M | $8.5M | $3.2M | $1.6M | $77.2M | $265.4M | |
| Stock Repurchase | -$13.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$39.1M | |
| Stock Based Comp. | $507.0K | $736.0K | $2.3M | $6.4M | $8.8M | $11.7M | $14.3M | $23.2M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | -78.7% | -114.7% | -23.1% | -30.0% | -33.8% | -57.2% | -77.6% | -73.2% | |
| ROA % | -65.3% | -100.5% | -22.0% | -26.2% | -30.0% | -47.6% | -62.7% | -37.6% | |
| ROIC % | -78.1% | -114.1% | -23.0% | -27.9% | -34.6% | -56.3% | -73.1% | -41.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | |
| Operating Income | 0.0% | 8.0% | -58.7% | -71.0% | -41.0% | -13.1% | -17.3% | |
| Net Income | 0.0% | 8.2% | -58.7% | -66.7% | -30.0% | -13.8% | -22.2% | |
| EPS (Diluted) | 0.0% | -12309.6% | -53.4% | -24.1% | 1.5% | 9.3% | -0.6% | |
| Operating Cash Flow | 0.0% | -17.7% | -33.3% | -68.5% | -16.9% | -25.0% | -6.2% | |
| Free Cash Flow | 0.0% | -9.6% | -37.6% | -61.3% | -15.9% | -25.6% | -5.1% | |
| R&D Expense | 0.0% | -5.6% | 39.5% | 67.9% | 51.4% | 14.6% | 23.2% | |
| SG&A Expense | 0.0% | -7.9% | 142.3% | 79.0% | 9.4% | 15.5% | -1.4% | |
| Total Assets | 0.0% | -40.3% | 624.0% | 39.9% | 13.9% | -28.5% | -7.2% | |
| Book Value / Share | 0.0% | 6194.2% | 686.8% | 25.3% | -12.7% | -46.3% | -25.9% | |
| Debt | 0.0% | -69.4% | 6400.0% | 2039.3% | -6.2% | -4.0% | -7.4% | |
| Diluted Shares | 0.0% | -99.0% | -0.0% | 2.5% | 32.3% | 25.3% | 21.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.97
10Y Low / Med / High1.55 / 2.69 / 1405.75
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.67
Tangible Book / Share
$3.32
Net Current Assets / Share
$2.86
Graham Net-Net
$3.07
Cash / Share
$3.41
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1783.13 | -14.37 | -10.75 | -5.36 | -4.59 | -4.70 | -3.10 | -3.69 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 1405.75 | 22.33 | 3.26 | 1.61 | 1.55 | 2.69 | 2.40 | 1.97 | |
| EV/EBITDA | -1824.39 | -19.42 | -10.11 | -3.71 | -4.40 | -4.62 | -2.73 | -4.75 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
9.97
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $19.2M | $4.9M | $34.1M |
| Net Income | -$100.2M | -$91.6M | -$72.2M |
| EPS | $-1.67 | $-1.52 | $-1.20 |
| # Analysts (EPS) | 3 | 3 | 2 |